Trials / Completed
CompletedNCT02696798
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 316 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2016-04-12
- Primary completion
- 2018-05-18
- Completion
- 2019-05-03
- First posted
- 2016-03-02
- Last updated
- 2020-06-17
- Results posted
- 2019-10-30
Locations
99 sites across 17 countries: United States, Argentina, Brazil, Canada, Finland, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02696798. Inclusion in this directory is not an endorsement.